Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasm Metastasis × exemestane × Clear all

Phase

Phase 2 6 Phase 3 3 Phase 4 2 Phase 1 2 Phase NA 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Premenopausal Breast Cancer 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Breast Diseases 1

Interventions

pembrolizumab 36 Nivolumab 20 Gemcitabine 18 Paclitaxel 17 Cyclophosphamide 17 Capecitabine 16 fludarabine 11 aldesleukin 11 Ipilimumab 11 130-nm albumin-bound paclitaxel 10 Docetaxel 9 Trastuzumab 8 Albumin-Bound Paclitaxel 8 Radiosurgery 7 Interleukin-2 7 Biopsy 7 Bevacizumab 7 fludarabine phosphate 6 Temozolomide 6 Specimen Handling 6 Irinotecan 6 Fluorouracil 6 Cisplatin 6 Cetuximab 6 Carboplatin 6 avelumab 5 Radiotherapy 5 Pemetrexed 5 Oxaliplatin 5 Magnetic Resonance Spectroscopy 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00905021 2020-07-24

EXTENT

Baylor Breast Care Center

Phase 1/2 Terminated

4 enrolled 6 charts

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡